Medication use and disease control of asthmatic patients in Flanders: A cross-sectional community pharmacy study

Respiratory Medicine

Volumn 100, Issue 8, 2006, Pages 1407-1414

  Mehuys, E ^a   Van Bortel, L ^b   Annemans, L ^c   Remon, J P ^a   Van Tongelen, I ^a   Van Ganse, E ^d   Laforest, L ^d   Chamba, G ^d   Brusselle, G ^e  

^a GHENT UNIVERSITY   (Belgium)

^b GHENT UNIVERSITY   (Belgium)

^c GHENT UNIVERSITY   (Belgium)

^d UNIVERSITÉ DE LYON   (France)

^e GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Asthma; Asthma control; Disease management; Pharmaceutical care; Pharmacotherapy

Indexed keywords

ANTIBIOTIC AGENT; ANTIHISTAMINIC AGENT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE PLUS FORMOTEROL; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; FLUTICASONE PROPIONATE PLUS SALMETEROL; LEUKOTRIENE RECEPTOR AFFECTING AGENT; LONG ACTING DRUG; SHORT ACTING DRUG; THEOPHYLLINE; XANTHINE DERIVATIVE;

ADULT; ARTICLE; ASTHMA; CLINICAL ASSESSMENT TOOL; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE CONTROL; DRUG SAFETY; DRUG USE; FATIGUE; FEMALE; HEADACHE; HEALTH SURVEY; HEART PALPITATION; HOARSENESS; HUMAN; INSOMNIA; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MEDICAL SPECIALIST; NEUROTOXICITY; PATIENT REFERRAL; PEAK EXPIRATORY FLOW; PHARMACY; PRESCRIPTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCORING SYSTEM; SELF CONCEPT; SYMPTOM; THROAT IRRITATION; VALIDITY;

ADULT; ANTI-ASTHMATIC AGENTS; ASTHMA; BELGIUM; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; MALE; PATIENT COMPLIANCE; PEAK EXPIRATORY FLOW RATE; RESPIRATORY FUNCTION TESTS; RETROSPECTIVE STUDIES;

EID: 33745412162     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rmed.2005.11.013     Document Type: Article

References (23)

1. Masoli M., Fabian D., Holt S., and Beasly R. The global burden of asthma: executive summary of the GINA Dissemination Committee Report. Allergy 59 (2004) 469-478
2. Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention: NHLBI/WHO Workshop Report. Bethesda: National Institutes of Health, National Heart, Lung and Blood Institute; 2002. Publication No. 02-3659.
3. British Thoracic Society. Scottish Intercollegiate Guidelines Network. British guideline on the management of asthma. Thorax 58 Suppl 1 (2003) 1-94
4. National Asthma Education and Prevention Program. Guidelines for the diagnosis and management of asthma: expert panel report 2. Betheseda: National Institutes of Health, National Heart, Lung and Blood Institute; 1997. Publication No. 97-4051.
5. Rabe K.F., Adachi M., Lai C.K.W., et al. Worldwide severity and control of asthma in children and adults: the global asthma insights and reality surveys. J Allergy Clin Immunol 114 (2004) 40-47
6. Nathan R.A., Sorkness C.A., Kosinski M., et al. Development of the Asthma Control Test: a survey for assessing asthma control. J Allergy Clin Immunol 113 (2004) 59-65
7. Mehuys E., Van Bortel L., Annemans L., et al. Medication use and disease control of asthma patients in flanders: a community pharmacy study. Eur Resp Soc Meeting Copenhagen A 319 (2005)
8. Gregg I., and Nunn A.J. Peak expiratory flow in normal subjects. Brit Med J 3 (1973) 282-284
9. Laforest L., Van Ganse E., Devouassoux G., et al. Quality of asthma care: results from a community pharmacy based survey. Allergy 60 (2005) 1505-1510
10. Bateman E.D., Boushey H.A., Bousquet J., et al. Can guideline-defined asthma control be achieved? The gaining optimal asthma control study. Am J Respir Crit Care Med 170 (2004) 836-844
11. Grainger-Rousseau T.J., Miralles M.A., et al. Therapeutic outcomes monitoring : application of pharmaceutical care guidelines to community pharmacy. J Am Pharm Assoc NS37 (1997) 647-661
12. Hepler C.D., and Strand L.M. Opportunities and responsibilities in pharmaceutical care. Am J Hosp Pharm 47 (1990) 533-543
13. Hepler C.D. TOM Research Group. Asthma TOM-Manual (1992), University of Florida, Gainesville, FL
14. 1. Am J Respir Crit Care Med 169 (2004) A319
15. Griffith S. A review of the factors associated with patient compliance and the taking of medicine. Br J Gen Pract 40 (1990) 114-116
16. Gibson P.G., Powell H., Coughlan J., et al. Self-management education and regular practitioner review for adults with asthma. Cochrane Database Syst Rev 1 (2004) CD001117
17. McLean W.M., and MacKeigan L.D. When does pharmaceutical care impact health outcomes? A comparison of community pharmacy-based studies if pharmaceutical care for patients with asthma. Ann Pharmacother 39 (2005) 625-631
18. Schulz M., Verheyen F., Muhlig S., et al. Pharmaceutical care services for asthmatic patients: a controlled intervention study. J Clin Pharmacol 41 (2001) 668-676
19. Weinberger M., Murray M.D., Marrero D.G., et al. Effectiveness of pharmacist care for patients with reactive airways disease-a randomized controlled trial. JAMA 288 (2002) 1594-1602
20. Stergachis A., Gardner J.S., Anderson M.T., and Sullivan S.D. Improving pediatric asthma outcomes in the community setting: does pharmaceutical care make a difference. J Am Pharm Assoc 42 (2002) 743-752
21. McLean W., Waller R., and Gillis J. The BC community pharmacy study: a study of clinical, economic, and holistic outcomes influenced by an asthma care protocol provided by specially trained community pharmacists in British Columbia. Can Resp J 10 (2003) 195-202
22. Bousquet J., Van Cauwenberge P., and Khaltaev N. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 108 5 Suppl (2001) S147-S334
23. Braunstahl G.J. The unified immune system: respiratory tract-nasobronchial interaction mechanisms in allergic airway disease. J Allergy Clin Immunol 115 (2005) 142-148